Repotrectinib and Osimertinib: Interaction Details
- Osimertinib
- Tagrisso
- Repotrectinib
- Augtyro
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Repotrectinib and Osimertinib interaction:
Repotrectinib
- Augtyro
What Happens When You Take Repotrectinib With Osimertinib
What can happen when they are taken together (rated Major)
Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Repotrectinib should not be taken together with . Giving a P-gp alongside repotrectinib can raise repotrectinib exposure, and this in turn may make adverse reactions to repotrectinib more frequent and more severe. In drug interaction studies, with itraconazole (a strong and P-gp inhibitor) raised repotrectinib (0 to inf) 5.9-fold and 1.7-fold.1
The Repotrectinib and Osimertinib Interaction, Explained
Osimertinib (Tagrisso) can raise the level of repotrectinib (Augtyro) in your body. Osimertinib blocks a "pump" called that normally helps move repotrectinib out of the body. With the pump slowed, more repotrectinib can build up, which may make side effects more likely or more intense. Repotrectinib's known side effects include dizziness, changes in taste, numbness or tingling, constipation, and trouble with balance or thinking.
Keep taking both medicines as prescribed and do not change anything on your own. Please tell your pharmacist or doctor that you take both, and report any new or worsening side effects. Your care team can watch you closely and decide the safest plan.
Mechanism: Osimertinib inhibits -mediated efflux of repotrectinib, a P-gp , which is expected to increase repotrectinib exposure. Direction: increased repotrectinib exposure and adverse reactions (e.g., effects, dizziness, ataxia, dysgeusia, paresthesia, ).
- Magnitude: not quantified for osimertinib. With itraconazole (strong and P-gp ), repotrectinib AUC0-inf rose 5.9-fold and 1.7-fold, though this reflects combined CYP3A and P-gp .
- Onset: unspecified. Evidence: probable.
- Management: labeling advises avoiding P-gp . If is unavoidable, monitor closely for repotrectinib toxicity and consider individualized dosing per prescriber judgment.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Repotrectinib and Osimertinib Interact
The likely mechanism
of -mediated efflux transport of repotrectinib
How to Manage the Repotrectinib and Osimertinib Interaction
The documented advice is to avoid using repotrectinib together with such as osimertinib when possible. Your care team will decide whether this combination is needed for you.
- Keep taking both medicines exactly as prescribed until your prescriber or pharmacist tells you otherwise.
- Make sure both your pharmacist and your prescriber know you take both drugs.
- Report new or worsening side effects, such as dizziness, balance problems, numbness or tingling, or changes in taste or thinking.
If the combination is continued, your team may monitor you more closely and the dose may need to be adjusted and individualized by your care team.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Repotrectinib or Osimertinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: AUGTYRO oral capsules, repotrectinib oral capsules
In drug interaction studies, with itraconazole (a strong and ) raised repotrectinib (0 to inf) 5.9-fold and 1.7-fold.1
Repotrectinib and Osimertinib: Common Questions
How serious is the Repotrectinib and Osimertinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Repotrectinib and Osimertinib interaction managed?
The documented advice is to avoid using repotrectinib together with such as osimertinib when possible. Your care team will decide whether this combination is needed for you. Keep taking both medicines exactly as prescribed until your prescriber or pharmacist tells you otherwise. Make sure both your pharmacist and your prescriber know you take both drugs. Report new or worsening sid… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Ask About the Repotrectinib and Osimertinib Interaction
Ask in your own words about taking Repotrectinib and Osimertinib together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: AUGTYRO(TM) oral capsules, repotrectinib oral capsules. Bristol-Myers Squibb Company (per FDA), Princeton, NJ, 2023. DailyMed
Other Serious Interactions of Repotrectinib and Osimertinib
Also serious with Osimertinib
- ColchicineContraindicated
- DronedaroneContraindicated
- LevoketoconazoleContraindicated
- PimozideContraindicated
Also serious with Repotrectinib
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Repotrectinib
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- WineMajor
- BeerMajor
- Siberian CockleburMajor
- Vitamin EModerate
- Vitamin AModerate
- + 182 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven. This interaction.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.